Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

Stock Information for Abpro Holdings Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Abpro Holdings Inc

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Statement on the Departure of Former CEO Ian Chan
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.